Track Taysha Gene Therapies, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Taysha Gene Therapies, Inc. TSHA · Stock Open Taysha Gene Therapies, Inc. in new tab

4.10 USD
EPS
-0.42
P/B
3.74
ROE
-54.18
Beta
1.31
Target Price
13.00 USD
Loading chart...
Key Metrics
Earnings dateMarch 3, 2027
EPS-0.42
Book Value1.10
Price to Book3.74
Debt/Equity15.29
% Insiders9.568%
Growth
Revenue Growth1.71%
Estimates
Forward P/E-10.58
Forward EPS-0.39
Target Mean Price13.00

DCF valuation

Model fair value for Taysha Gene Therapies, Inc. (TSHA)
Result
Sign in to run the valuation for TSHA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
13 analysts · consensus Strong buy · mean target 13.00 USD (low 9.00, high 19.00) · as of 15 Nov 2026
Low 9.00
Mean 13.00
High 19.00
Price 4.10
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Taysha Gene Therapies, Inc. Logo Taysha Gene Therapies, Inc. Analysis (TSHA)

United States Health Care Official Website Stock

Is Taysha Gene Therapies, Inc. a good investment? Taysha Gene Therapies, Inc. (TSHA) is currently trading at 4.10 USD. Market analysts have a consensus price target of 13.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: Taysha Gene Therapies, Inc. is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is -0.39.

Investor FAQ

Does Taysha Gene Therapies, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Taysha Gene Therapies, Inc.?

Taysha Gene Therapies, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of -0.42.

Company Profile

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Exchange Ticker
NMS (United States) TSHA
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion